BioMarin to Acquire Alesta Therapeutics in Deal Valued at $490 Million to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia
On Aug. 18, 2026, BioMarin Pharmaceutical announced a definitive agreement to acquire Alesta Therapeutics to gain Alesta’s lead…